Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
| Market Capitalization | $15.0308 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.283 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.1 |
| EBITDA | |
| Profit Margin | 0 |
| Operating Margin TTM | -18.6173 |
| Return on Assets TTM | -0.2043 |
| Return on Equity TTM | -0.3118 |
| Revenue TTM | 459.085 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2019-06-30 | 0.13 | 0.396 | 381.456 | |
| 2020-06-30 | 165.7 | 3,408.036 | ||
| 2021-06-30 | 158.79 | 2,442.696 | ||
| 2022-06-30 | 262.13 | 4,241.68 | ||
| 2023-06-30 | 1,256.17 | 8,979.286 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2019-06-30 | 12,170.247 | 12,373.81 | 935.49 | 0 | 12,609.756 | |
| 2020-06-30 | 26,300.459 | 26,417.341 | 2,015.373 | 0 | 27,017.127 | |
| 2021-06-30 | 32,716.091 | 32,737.29 | 658.614 | 0 | 36,413.432 | |
| 2022-06-30 | 29,339.382 | 29,485.097 | 1,004.214 | 0 | 36,413.432 | |
| 2023-06-30 | 22,470.243 | 22,803.808 | 1,572.37 | 0 | 36,413.432 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2019-06-30 | -696.366 | -690.396 | 36,510.741 | 12,170.247 | ||
| 2020-06-30 | -3,430.468 | -1,603.393 | 14,130.212 | 12,170.247 | 26,300.459 | |
| 2021-06-30 | -2,125.126 | -1,678.245 | 6,415.632 | 26,300.459 | 32,716.091 | |
| 2022-06-30 | -3,584.719 | -3,584.719 | -3,376.709 | 32,716.091 | 29,339.382 | |
| 2023-06-30 | -7,749.856 | -6,869.14 | -6,869.139 | 29,339.382 | 22,470.243 |